03/06/2026
🥜 Let’s Talk About the Stanford Peanut Patch Study.
Why am I pushing back?
From what’s being proposed, infants with peanut allergy may be randomized to either a placebo or the peanut patch to see if it works.
Here’s my issue:
In 2026, the standard of care for infants with peanut allergy is evolving toward early oral immunotherapy and structured food introduction — not placebo. We already have strong real-world experience showing that carefully dosed peanut protein by mouth can work very well in this age group.
So if you’re going to study a patch, compare it to oral immunotherapy in infants. That’s a meaningful question.
But placebo vs. patch? That feels outdated.
And here’s my bigger concern:
If the patch gets approved, there will likely be a massive marketing push. Multi-million-dollar campaigns. Key opinion leaders. Messaging that this is “the solution.”
We’ve seen that play out before with Palforzia — strong branding around something that, at its core, was still peanut protein therapy.
Money doesn’t mean something is bad.
But money absolutely shapes the narrative.
Do I think there may be a very small subset of toddlers who might benefit from a patch? Possibly.
Do I see most of my infant peanut patients needing it if approved? No.
In my practice, we can usually accomplish protection through carefully structured oral introduction — without a device, without a patch, and without the added cost layer.
My job isn’t to hype or to tear down.
It’s to talk to you like family and help you think critically.
If you’re considering enrolling in a patch study or just confused about your options, I’m happy to walk through the pros, cons, and what I’d realistically recommend.
Marketing is loud.
Data matters more.
📞: (678) 325-3788
💻: Schedule an appointment — https://bit.ly/4aW4Jf2
📍14 Convenient Locations: Alpharetta, Atlanta, Buford, Canton, Cu***ng, Druid Hills, Duluth, Johns Creek, Lawrenceville, Marietta, Midtown Atlanta, Peachtree Corners, Vinings, Woodstock